ArticleIranian biomedical journal2025
Effects of Cabergoline on Embryo Growth: Macroscopic and Molecular Findings.
Article in Iranian biomedical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prolactin is a neurohypophyseal hormone that plays a major role in behavior, growth, and angiogenesis. CAB suppresses the effects of PRL by targeting the D2R. In this study, we used in silico and in vivo approaches to examine the side effects of CAB using chicken as a model. Methods: Thirty fertilized eggs were equally divided into three groups: one control and two experimental groups treated with CAB at doses of 0.5 mg/kg and 1 mg/kg, respectively. After 18 days of experiment, embryo weight, average body length, chorioallantoic vessels length, and relative PRL gene expression were analyzed. Also, prolactin-protein interaction and functional pathways regulated by PRL and associated proteins were investigated using the STRING database. Results: Macroscopic analysis showed a significant increase (17.54 ± 0.28) and decrease (12.92 ± 0.38) in weight in the 0.5 mg/kg and 1 mg/kg groups, respectively, as compared to the control. A significant reduction in body size and an increase in chorionic vessel development were observed only in the 0.5 mg/kg group. PRL expression levels significantly decreased in both CAB-treated groups. In silico analysis revealed PRL interactions with INS and POMC proteins, which are conserved between H. sapiens and G. gallus. Conclusion: Our findings indicate that CAB not only reduces prolactin levels but also affects fetal weight and body size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.